"Receptors, Estrogen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of estrogen receptors in breast cancer patients has become clinically important.
| Descriptor ID |
D011960
|
| MeSH Number(s) |
D12.776.826.750.350 D12.776.930.778.350
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Receptors, Estrogen".
Below are MeSH descriptors whose meaning is more specific than "Receptors, Estrogen".
This graph shows the total number of publications written about "Receptors, Estrogen" by people in this website by year, and whether "Receptors, Estrogen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 6 | 2 | 8 |
| 1996 | 3 | 4 | 7 |
| 1997 | 9 | 4 | 13 |
| 1998 | 6 | 4 | 10 |
| 1999 | 7 | 8 | 15 |
| 2000 | 10 | 5 | 15 |
| 2001 | 13 | 6 | 19 |
| 2002 | 7 | 6 | 13 |
| 2003 | 10 | 5 | 15 |
| 2004 | 7 | 8 | 15 |
| 2005 | 13 | 10 | 23 |
| 2006 | 7 | 10 | 17 |
| 2007 | 11 | 4 | 15 |
| 2008 | 3 | 6 | 9 |
| 2009 | 6 | 9 | 15 |
| 2010 | 10 | 7 | 17 |
| 2011 | 8 | 9 | 17 |
| 2012 | 10 | 6 | 16 |
| 2013 | 5 | 8 | 13 |
| 2014 | 3 | 7 | 10 |
| 2015 | 10 | 7 | 17 |
| 2016 | 4 | 2 | 6 |
| 2017 | 3 | 9 | 12 |
| 2018 | 4 | 10 | 14 |
| 2019 | 3 | 6 | 9 |
| 2020 | 1 | 5 | 6 |
| 2021 | 2 | 5 | 7 |
| 2022 | 0 | 8 | 8 |
| 2023 | 1 | 5 | 6 |
| 2024 | 4 | 3 | 7 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptors, Estrogen" by people in Profiles.
-
ASO Visual Abstract: Real-World Implications of the SOUND Trial. Ann Surg Oncol. 2025 Jan; 32(1):121-122.
-
A Preoperative Window-of-Opportunity Study of Oral SERD, Imlunestrant, in Newly Diagnosed ER-Positive, HER2-Negative Early Breast Cancer: Results from the EMBER-2 Study. Clin Cancer Res. 2024 Dec 02; 30(23):5304-5313.
-
Real-world quality-of-life of patients with HR+/HER2-?advanced breast cancer treated with palbociclib plus endocrine therapy: EORTC QLQ-C30 results from POLARIS. Breast Cancer Res Treat. 2025 Feb; 209(3):613-627.
-
Differential bone morphology and hypoxia activity in skeletal metastases of ER+ and ER- breast cancer. Commun Biol. 2024 Nov 21; 7(1):1545.
-
Estrogen Signaling in Early-Stage Breast Cancer: Impact on Neoadjuvant Chemotherapy and Immunotherapy. Cancer Treat Rev. 2025 Jan; 132:102852.
-
Neoadjuvant Radiotherapy and Endocrine Therapy for Oestrogen Receptor Positive Breast Cancers: The Neo-RT Feasibility Study. Clin Oncol (R Coll Radiol). 2025 Jan; 37:103669.
-
Significance of Residual Nodal Disease in Clinically Node-Negative Breast Cancer After Neoadjuvant Chemotherapy. Ann Surg Oncol. 2025 Feb; 32(2):922-930.
-
Nuclear staining for pan-Trk by immunohistochemistry is highly specific for secretory carcinoma of breast: pan-Trk in various subtypes of breast carcinoma. J Clin Pathol. 2024 Oct 20; 77(11):751-755.
-
Real-World Implications of the SOUND Trial. Ann Surg Oncol. 2024 Dec; 31(13):8776-8785.
-
PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer. Mol Cancer Ther. 2024 Oct 01; 23(10):1494-1510.